- Raw materials
- Anticancer drugs
- Methylselenocysteine
Se-methyl-seleno-l-cysteine (Methylselenocysteine) API Manufacturers & Suppliers
0 verified results
All Methylselenocysteine data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Methylselenocysteine | CAS No: 26046-90-2 | GMP-certified suppliers
A medication that is under investigation for potential use in cancer prevention, particularly prostate carcinoma, by providing protective antioxidant properties linked to selenium.
Therapeutic categories
Product Snapshot
- Methylselenocysteine is an oral small molecule formulation
- It is primarily investigated for use in oncology and chemoprevention applications
- The compound is currently in investigational phases and has not received FDA or EMA approval
Clinical Overview
Although not approved for therapeutic use, methylselenocysteine has been studied in clinical trials focusing on the prevention of prostate carcinoma and management of disease remission states. The compound’s incorporation of selenium, an element known to have roles in antioxidant defense and cellular protection, relates to its investigational interest in oncology. Its pharmacodynamics and precise mechanism of action remain incompletely characterized; however, its categorization as an anticarcinogenic and protective agent suggests involvement in modulating oxidative damage and influencing cellular pathways linked to carcinogenesis.
Key pharmacokinetic parameters, including absorption, distribution, metabolism, and excretion (ADME), are not fully delineated for methylselenocysteine due to its investigational status. Selenium-containing amino acids generally undergo metabolic conversion to bioactive selenium metabolites, which may contribute to biological effects. Safety and toxicity data specific to methylselenocysteine are limited, and no formal approval for clinical use has been granted. Careful evaluation in controlled research environments is essential, given potential selenium toxicity at supraphysiological doses.
Methylselenocysteine remains a compound of interest primarily within research, pharmaceutical development, and industrial settings rather than established clinical therapeutics. Procurement of methylselenocysteine API should involve stringent quality control measures to ensure purity, stability, and compliance with regulatory standards for investigational substances. Reliable sourcing should confirm certified origin and appropriate documentation to support research and development applications.
Identification & chemistry
| Generic name | Methylselenocysteine |
|---|---|
| Molecule type | Small molecule |
| CAS | 26046-90-2 |
| UNII | TWK220499Z |
| DrugBank ID | DB12697 |
Formulation & handling
- Methylselenocysteine is a small molecule with high water solubility, suitable for oral formulation.
- The compound's low LogP value indicates poor lipid membrane permeability, which may affect absorption.
- As an investigational amino acid derivative, it requires careful consideration of stability during storage and formulation.
Regulatory status
Methylselenocysteine is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
